Maqola

Analysis of Immune and Inflammatory Microenvironment Characteristics of Noncancer End-Stage Liver Disease

Yang WangBeijing YouAn HospitalQi WangOrgan Transplant Center, The Affiliated Hospital of Qingdao University, Qingdao, ChinaTong Wang YangOrgan Transplant Center, The Affiliated Hospital of Qingdao University, Qingdao, ChinaJi Ming YinBeijing YouAn HospitalFeili WeiBeijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing, ChinaHuan LiuAffiliated Hospital of Qingdao UniversityPeng Xiang YangBeijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing, ChinaJiaxi LiBeijing YouAn HospitalNing LiuBeijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing, ChinaYunxia ZhuYunxia Zhu, Beijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing 100069, ChinaDexi ChenBeijing Institute of Hepatology, Beijing You An Hospital, Capital Medical University, Beijing, China

2023en

ABI

Annotatsiya

Chronic liver injury eventually progresses to cirrhosis and end-stage liver disease (ESLD), which are the leading causes of death in patients with liver disease worldwide. ESLD has a variety of etiologies and a complex pathogenesis. This study analyzed the characteristics of ESLD by studying the immune microenvironment and inflammatory microenvironment of ESLD caused by 4 noncancer diseases, including HBV-ALF, ALF, AILD, and AH. We collected transcriptome data from noncancer ESLD patients, collected liver tissue samples and blood samples from ESLD liver transplant patients, and analyzed the immune and inflammatory microenvironments in the liver and blood. The results showed that with the exception of HBV-induced ESLD, there were no significant differences in immune microenvironment scores among patients with ESLD caused by other noncancer diseases. Moreover, there were no significant differences in the inflammatory microenvironment in the liver and blood of patients with ESLD caused by the 4 noncancer diseases. Furthermore, we found that the cytokine, IL-15, could predict the prognosis of ESLD patients.

Hali tarjima qilinmagan

Identifikatorlar

DOI: 10.1089/jir.2022.0172

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba